French Polynesia vs New Zealand: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
French Polynesia
0.0%
in 2024
New Zealand
0.0%
in 2024
French Polynesia rank
167th
New Zealand rank
167th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- French Polynesia
- New Zealand
How they compare
French Polynesia currently reports 0.0% against 0.0% in New Zealand, a difference of 0.0%.
Across all 10 years both countries report, New Zealand has been ahead every year.
French Polynesia ranks 167th and New Zealand ranks 167th of 246 countries.
New Zealand has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | French Polynesia | New Zealand | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.0% | 0.1% | 0.1% | New Zealand |
| 2020s | 0.0% | 0.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, French Polynesia or New Zealand?
- French Polynesia, at 0.0% against 0.0% in New Zealand as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between French Polynesia and New Zealand?
- 0.0%, with French Polynesia ahead.
- How many years of comparable data are there for French Polynesia and New Zealand?
- 10 years are reported by both, from 2015 to 2024.
- How do French Polynesia and New Zealand rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- French Polynesia ranks 167th and New Zealand ranks 167th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.